Skip to main content
Search

Caner Saygin, MD

Dr. Saygin’s laboratory investigates the biology of leukemia using both in vitro and in vivo models of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as human samples from patients with these malignancies. A key focus of the lab is understanding the drivers of clonal hematopoiesis of indeterminate potential (CHIP) and its progression to leukemias of either myeloid or lymphoid lineage, in both de novo and therapy-related contexts.



The overarching goal of Dr. Saygin’s translational research program is to identify the molecular and cellular mechanisms that drive these fatal diseases and to translate those insights into novel therapeutic strategies. The lab’s drug development efforts are particularly focused on high-risk subsets of AML and ALL and have resulted in the launch of investigator-initiated phase I/II clinical trials originating directly from discoveries made in the lab.